Russell Investments Group
PVLA

Russell Investments Group’s Palvella Therapeutics PVLA Stock Holding History

Russell Investments Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
13,527
+12,298
+1,001% +$1.28M ﹤0.01% 1959
2025
Q4 		$129K Buy
1,229
+661
+116% +$56.4K ﹤0.01% 2971
2025
Q3 		$35.6K Buy
+568
New +$25.3K ﹤0.01% 3409
2021
Q2 		– Sell
-23
Closed -$4K – 3308
2021
Q1 		$4K Sell
23
-1,031
-98% -$225K ﹤0.01% 3081
2020
Q4 		$210K Sell
1,054
-2,304
-69% -$479K ﹤0.01% 2745
2020
Q3 		$555K Buy
3,358
+3,105
+1,227% +$707K ﹤0.01% 2345
2020
Q2 		$62K Hold
253
– – ﹤0.01% 2961
2020
Q1 		$45K Buy
+253
New +$63.8K ﹤0.01% 2878
2018
Q3 		– Sell
-76
Closed -$31K – 3025
2018
Q2 		$31K Sell
76
-24
-24% -$11.4K ﹤0.01% 2858
2018
Q1 		$54K Hold
100
– – ﹤0.01% 2820
2017
Q4 		$59K Buy
+100
New +$46.5K ﹤0.01% 2849

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Russell Investments Group's PVLA Position: Q1 2026 in Review

Russell Investments Group increased its Palvella Therapeutics (PVLA) stake by 1,001% in Q1 2026, buying an estimated $1.28M and bringing the position to 13,527 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Russell Investments Group first reported a position in PVLA in Q4 2017 and has held it in 11 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Russell Investments Group held 13,527 shares of Palvella Therapeutics worth $1.69M as of Q1 2026.
  • Russell Investments Group bought 12,298 Palvella Therapeutics shares in Q1 2026, an estimated $1.28M.
  • Palvella Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #1959 holding.
  • Russell Investments Group first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 11 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.